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The tumour necrosis factor family member TNF-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in a
variety of cancer cells through the activation of death receptors 4 (DR4) and 5 (DR5) and is considered a promising anticancer
therapeutic agent. As apoptosis seems to occur primarily via only one of the two death receptors in many cancer cells, the
introduction of DR selectivity is thought to create more potent TRAIL agonists with superior therapeutic properties. By use of
a computer-aided structure-based design followed by rational combination of mutations, we obtained variants that signal
exclusively via DR4. Besides an enhanced selectivity, these TRAIL-DR4 agonists show superior afﬁnity to DR4, and a high
apoptosis-inducing activity against several TRAIL-sensitive and -resistant cancer cell lines in vitro. Intriguingly, combined
treatment of the DR4-selective variant and a DR5-selective TRAIL variant in cancer cell lines signalling by both death receptors
leads to a signiﬁcant increase in activity when compared with wild-type rhTRAIL or each single rhTRAIL variant. Our results
suggest that TRAIL induced apoptosis via high-afﬁnity and rapid-selective homotrimerization of each DR represent an important
step towards an efﬁcient cancer treatment.
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Tumour necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) is a promiscuous member of the TNF super-
family capable of binding to ﬁve different receptors. TRAIL
induces apoptosis via the death receptors (DRs) 4 and 5,
1–2
followed by recruitment of the Fas-associated death
domain.
3–5 Formation of the death-inducing signalling
complex (DISC) is completed by binding of procaspase-8
and -10, leading to their cleavage and activation, that in turn
activate downstream caspases (e.g. caspase-3), resulting
in apoptosis.
6–8 TRAIL binds also to three decoy receptors,
DcR1, DcR2 and OPG.
9 Decoy receptors lack a functional
deathdomain,andconsequently theydonotinduceapoptosis
and can prevent TRAIL binding to death receptors.
2,9–11
TRAIL is generating considerable interest as a possible
anticancer therapeutic agent because of its selective
activation of apoptosis in cancer cells.
12,13 The formation of
heterotrimeric non-apoptotic TRAIL–receptor complexes
7,14,15
and the receptor binding promiscuity of TRAIL endorsed the
concept that DR selectivity may allow the creation of more
potent TRAIL apoptosis inducers.
16–19 DR5 was described as
contributing more than DR4 to the overall apoptotic activity of
TRAIL in apoptosis signalling of cancer cells.
16,20,21 Recently,
DR4 has gained increased importance, with the realization
that certain cancer cells depend mainly on this receptor for
apoptosis via TRAIL.
17,18,22 Whereas potent DR5-selective
variants were created previously,
16,19 no enhancement of
apoptosis by selective activation of DR4 has been accom-
plished by using TRAIL variants. A previous generation of
DR4-selective variants designed by us
18 or by others
17 were
either equallyactivewhencompared withrhTRAIL
WTor largely
inactive.
16–17
Here we report the design of highly active, DR4-speciﬁc
TRAIL variants by using computational protein design
and a rational combination strategy. This resulted in the
ﬁrst DR4-selective variants that not only have an enhanced
selectivity to DR4, but also a signiﬁcant increase in apoptosis-
inducing activity in many cancer cells in vitro. Both receptor
selectivity and increased afﬁnity for DR4 appear to contribute
to the more efﬁcient apoptosis induction by these TRAIL
variants.
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www.nature.com/cddisThese DR4-selective variants and the previously described
DR5-selective variants
19 allowed us to establish the contribu-
tion of DRs in apoptosis signalling of different cancer cells.
Cell lines signalling via both DRs showed a large increase in
efﬁcacy upon combined treatment with selective TRAIL
variants when compared with rhTRAIL
WT. Our results show
thesenovelDR4-speciﬁcvariantsaloneorincombinationwith
a DR5-speciﬁc variant as a powerful strategy for targeting
DR4/DR5-responsive cancer cells.
Results
Computational design of variants using FoldX. A reﬁned
model of the DR4 receptor was created using FoldX.
All residues in the TRAIL–receptor interface were consi-
dered. A set of predicted energetic values for TRAIL–
receptor complex formation was obtained and compared
with the TRAIL
WT values. FoldX proposed the following
mutations to favour DR4 selectivity: R149I, R149M, R149N,
R149K, S159R, Q193H, Q193K, N199R, K201R, K204D,
K204E, K204L, K204Y, K212R, S215D, S215E, S215H,
S215K, K251D, K251E and K251Q. Mutations at position
218 were constructed before,
18 and were therefore not
considered.
DR4-selectivity screening. RhTRAIL variants were
expressed and puriﬁed as described before,
19,23 and
variants were characterized by surface plasmon resonance
(SPR). Apoptosis-induction assays were performed in cell
lines mediating apoptosis primarily via DR4 or DR5.
Mutations at positions 149, 159, 199, 201 and 215 showed
increased selectivity to DR4 as predicted by FoldX
(Supplementary Figure S1), whereas mutations at positions
193, 204, 212 and 251 did not show the expected changes.
Interestingly, positions 199, 201 and 215 have been found
before in DR4 variants selected by phage display.
16 Variants
showing an increase in binding ratio of DR4 over DR5
(DR4/DR5) of more than fourfold as measured by pre-steady
state SPR (Supplementary Table 1), and/or presenting a
more than threefold increased activity on DR4-mediated cell
lines, and showing inactivity in DR5-mediated cell lines were
chosen for further studies. R149I, S159R and S215D were
selected.
Rational combination of single variants. Several amino-
acid substitutions resulted in high DR4/DR5 binding ratios
relative to rhTRAIL
WT, thus favouring DR4 binding. The
characteristics of these single mutants were used for rational
design of nine combination variants, containing between
two and six mutations each. A single mutant (G131R)
constructed previously
23 showing increased afﬁnity to both
DRs and a double mutant (N199R; K201H), showing a
decrease in afﬁnity to DR5 have been combined before (to be
published elsewhere), and were therefore incorporated in the
new combination variants. Mutation S159R was incorporated
in all the combination variants, showing a high afﬁnity ratio
change (Supplementary Table 1). Mutants displaying similar
or higher binding afﬁnities to DR4, together with a lowered
afﬁnity for DR5, were characterized. Mutations that resulted
in more than 50-fold increased DR4/DR5 binding ratio
compared with rhTRAIL
WT as measured by SPR were
selected. Two combination variants showing the highest
afﬁnity increase to DR4 and afﬁnity decrease for DR5 were
selected for further studies. These variants were named
4C7 (G131R/R149I/S159R/N199R/K201H/S215D) and 4C9
(G131R/R149I/S159R/S215D).
Death receptor selectivity of 4C7 and 4C9. Binding of
rhTRAIL
WT and variants 4C7 and 4C9 to DRs using SPR
showed an increased afﬁnity to DR4-Ig with a 9–10-fold lower
dissociation constant (KD) when compared with rhTRAIL
WT
(Table 1). In contrast, 4C7 and 4C9 showed a much lower
afﬁnity to DR5-Ig with regard to rhTRAIL
WT with a 40- and
230-fold increase in dissociation constant to DR5-Ig for 4C9
and 4C7, respectively (Table 1). DR4-Ig competed with
a 5–7-fold increased effect for the variants 4C7 and 4C9
when compared with rhTRAIL
WT (Figure 1a). Inversely,
DR5-Ig was less capable to compete for 4C7 and 4C9
binding to immobilized DR4-Ig (Figure 1b). A 29-fold
increased binding of 4C9 to immobilized DR4-Ig was
observed compared with rhTRAIL
WT when competing with
DR5-Ig, indicating a preference to bind to DR4. 4C7 was
even less sensitive to competition by DR5-Ig, with 80%
binding efﬁciency for DR4 even when competing with
5000ng/ml of DR5-Ig. These results indicate that the
variants 4C7 and 4C9 bind highly preferentially to DR4.
Decoy receptors DcR1-Ig and DcR2-Ig were found to
equally compete for binding to rhTRAIL
WT 4C7 and 4C9
(Supplementary Figure S2). Interestingly, another combina-
tion variant (4C6: R149I/S159R/S215D) showed not only
lowered binding to DR5, but also decreased binding afﬁnity to
both decoy receptors in solution (Supplementary Figure S2).
Biological activity of DR4-selective variants. Comparison
between single variants and combination variants in BJAB
cell lines showed that 4C7 displays a greatly improved
capability to induce cell death when compared with
rhTRAIL
WT, to the single variants and to a combination of
three mutations (Supplementary Figure S3). To conﬁrm the
selectivity of 4C7 and 4C9 in vitro, we tested their activity in
Table 1 Kinetic parameters of trimer–monomer complex using surface
plasmon resonance
DR4-Ig
Protein ka (/M/s)
a kd (s
 1)
b KD (nM)
c
WT (7.45±0.4) 10
5 (1.66±0.3) 10
 4 0.22±0.06
4C7 (28.1±1.7) 10
5 (0.59±0.3) 10
 4 0.021±0.01
4C9 (23.5±1.4) 10
5 (0.58±0.4) 10
 4 0.025±0.02
DR5-Ig
WT (13.9±1.5) 10
5 (0.65±0.3) 10
 4 0.033±0.03
4C7 (1.14±0.5) 10
5 (8.48±0.8) 10
 4 7.41±4.2
d
4C9 (19.0±0.7) 10
5 (23.1±1.2) 10
 4 1.22±0.2
d
aAssociation rate constant.
bDissociation rate constant.
cEquilibrium dissocia-
tionconstant(kd/ka).Eachvalue wascalculated using the BIAcore3000and the
BIA evaluation 4.1 software.
dCurves showed heterogeneity, a phenomenon
that may be correlated to partial glycosylation of receptors
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Cell Death and Diseasedifferent cell lines mediating apoptosis via different DRs.
Analysis of cell death induction in Burkitt’s lymphoma BJAB
cells inducible by both DR4 and DR5 (BJAB
WT) and BJAB
cells deﬁcient in DR5 (BJAB
DR5 DEF)
24 showed that 4C7 and
4C9 do not require DR5 to deliver similar levels of apoptosis
in both cell lines. In addition, 4C7 and 4C9 showed a
signiﬁcant increase in cell death induction in BJAB cells when
compared with rhTRAIL
WT in all concentrations measured
(Figure 2a and b).
Cell assays in DR5-mediating A2780 and Jurkat cells
showed no apoptosis-inducing activity of the variants (o10%)
at almost all concentrations measured (Figure 2c and d).
These results support that 4C7 and 4C9 induce apoptosis
essentially via DR4. Furthermore, enhanced activity of TRAIL
variants 4C7 and 4C9 was shown on a number of colon
adenocarcinoma cells sensitive to TRAIL-induced apoptosis
when compared with rhTRAIL
WT, including Colo205, SW948,
HCT-15 and DLD-1 (Figure 3a–d).
Areductionof3–5-foldincellviabilityofColo205byvariants
4C7 and 4C9 when compared with rhTRAIL
WT was observed
(Figure 3a). The SW948 cell line showed a strong decrease in
cell viability upon treatment with the variants (Figure 3b).
Moreover, an impressive decrease in cell viability has been
obtained in HCT-15 and DLD-1 cell lines by 4C7 and 4C9
when compared with rhTRAIL
WT (up to 88% cell death)
(Figure 3c and d). Our results indicate that these cell lines can
Figure 1 Competitive inhibition by TRAIL death receptors for rhTRAIL
WT and variants 4C7 and 4C9, binding to immobilizedDR4-Ig, usingsoluble DR4-Ig as a competitor
(a) and soluble DR5-Ig as a competitor (b), in the presence of 100ng/ml of rhTRAIL
WT or variants and 0–5000ng/ml per well of DR4- or DR5-Ig. Binding of rhTRAIL
WT and
variants was measured relative to the wells containing no soluble receptor
Figure2 Deathreceptor4selectivityofvariantsinseveralcelllines.Celldeathinductionbywild-typeTRAILandvariantson(a)BJABcelllinemediatingapoptosisviaboth
DR4 and DR5 receptors (BJAB
WT), (b) BJAB DR5-deﬁcient cell line (BJAB
DR5 DEF) mediating apoptosis via DR4, (c) DR5-mediated Jurkat leukaemia and (d) DR5-mediated
A2780ovarian carcinomacells. BJABcells were treated with rhTRAIL
WT and variants for 24h. The percentage of cell death was calculatedrelative to control wells containing
no ligand. Jurkat leukaemia cells and A2780 ovarian carcinoma cancer cells were treated with the indicated concentrations of rhTRAIL
WT and variants for 24h, after which
induction of cell death was measured by Annexin V staining. The results are mean values±S.E.M. (n¼3)
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Cell Death and Diseasebe triggered very efﬁciently to undergo apoptosis by these
novel DR4-speciﬁc variants.
We then tested whether selective activation of DR4 would
have an impact on cancer cell lines less sensitive to TRAIL-
induced apoptosis. Remarkably, our variants 4C7 and 4C9
showed a signiﬁcant increase in cell killing in breast cancer
MCF-7 and pancreatic cancer PANC-1 cell lines (Figure 3e
and f). Both cell lines express DR4 and DR5 on their surface
(Supplementary Figure S4). Furthermore, the variants were
tested for activity on normal cells, namely ﬁbroblasts. No
signiﬁcant activity for rhTRAIL
WT or variants 4C7 and 4C9
could be observed, suggesting that the increased apoptotic
activity on cancer cells had no effect on normal cells
(Supplementary Figure S5).
Real-time analysis of caspase activation. The variant 4C7
was subject of study by analysing caspase activation using
FRET. Activation of the initiator caspase-8/10 was followed
by using a probe based on CFP and YFP (Venus),
25
interconnected by a linker containing the preferred
cleavage motif for caspase-8 (IETD).
26,27 Owing to its high
signal/noise ratio, this probe allows the efﬁcient detection of
low caspase activities.
25 The 4C7 variant-induced proﬁle of
intracellular IETDase activity shows increased cleavage
of the CFP-IETD-Venus probe in ovarian carcinoma
OVCAR-3 cells at much earlier time points when compared
with rhTRAIL
WT (Figure 4). Cleavage by activated initiator
caspases could be observed within 15–20min after 4C7
addition. More signiﬁcant differences between rhTRAIL
WT
and 4C7 occur after 50min of incubation with 50 and
100ng/ml (Figure 4a and b). Effector caspases have also
been shown to cleave IETD recognition sites,
27 and conse-
quently a more rapid increase observed after cleavage by
activated caspase-8 is most likely owing to the activation of
Figure3 SeveralcancercelllinesundergoapoptosisefﬁcientlyviaTRAILDR4-selectivevariants.(a)Colo205,(b)SW948,(c)DLD-1and(d)HCT-15coloncarcinomacell
lineswereincubatedwithdifferentconcentrationsofrhTRAIL
WTandvariants4C7and4C9for24h,andassayedforcellviability.Thepercentageofviablecellswascalculated
relative to control wells containing no ligand. The results are mean values±S.E.M. (n¼3). Death receptor 4-selective variants induce higher levels of apoptosis in MCF-7
human breast adenocarcinoma (e) and PANC-1 human pancreatic carcinoma cells (f). Cells were treated with rhTRAIL
WT and variants 4C7 and 4C9 for 24h and cell death
was measured by Annexin V staining. The results are mean values±S.E.M. (n¼3)
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Cell Death and Diseaseeffector caspases during apoptosis or elevated caspase-8
activity, resulting from feedback via caspase-6. Analysis of
downstream activation of effector caspase-3/7 based on
DEVDase activity using a probe containing CFP and
YFP indicates that the rate of cleavage remains low at
initial time points, and raises rapidly after 75min over a
30–40min period for 4C7 (Figure 4c and d). The rate of
DEVDase cleavage for rhTRAIL
WT was substantially lower.
These results indicate a much faster and robust initiator and
effector caspase activation by variant 4C7 compared with
rhTRAIL
WT in living cells.
Combination of death receptor-selective variants. In
order to establish receptor activity in different cell lines, we
tested the new DR4-selective variants or our DR5-selective
mutant (D269H/E195R).
19 Most cell lines tested undergo
apoptosis primarily via one of the DRs; however, some cells
did show sensitivity via both DRs. We reasoned that selective
activation of both DRs by TRAIL variants may lead to an
additive effect in cell death induction and that targeting both
DRs separately may be of therapeutic relevance in cancer
cell lines. OVCAR-3 cells express both DRs, with almost
no detectable levels of decoy receptors (Supplementary
Figure S4). Both 4C7 (ED50¼6.61±1.3ng/ml) and 4C9
(ED50¼7.86±1.53ng/ml) caused a substantial decrease
in viability when compared with rhTRAIL
WT (ED50¼46.8±
1.1ng/ml), with the DR4-selective variants reaching cell
death levels of 88 and 83%, whereas rhTRAIL
WT was only
capable of 50% cell death induction at the highest concen-
tration measured (250ng/ml) (Figure 5a). Similarly, activation
of DR5 by D269H/E195R in this cell line resulted in increased
apoptosis induction, with a nearly sevenfold increase in
cell death compared with rhTRAIL
WT. Interestingly, the
combination of equimolar concentrations of DR4 and
DR5 TRAIL-selective variants resulted in an even lower cell
survival at all concentrations measured, when compared with
the single treatment with either only rhTRAIL
WT or selective
variants. At the highest concentration used, the combination
of selective variants was capable of killing almost 95%
of cells upon 24h incubation. In the Colo205 cell line, the
cooperation between DR4- and DR5-selective induction was
less pronounced, even though at high concentrations higher
levels of cell death could be shown (up to 94%). At these
concentrations, also a difference with D269H/E195R could
be observed (Figure 5b). In the colon carcinoma CL-34 cell
line, both 4C7- and DR5-speciﬁc variant showed higher
activities than rhTRAIL
WT at almost all concentrations and
when combined induced higher killing levels compared
Figure 4 TRAIL-induced IETDase and DEVDase proﬁles of rhTRAIL
WT and variant 4C7 in OVCAR-3 ovarian carcinoma cell line. Cells were treated with two different
concentrations of rhTRAIL
WT and 4C7,(a)50ng/ml and (b)100ng/ml.IETDaseactivity proﬁle displayedFRET cleavageandconsequentincrease inCFP/YFPemission ratio
is plotted. (c) DEVDase activities displaying FRET cleavage upon addition of 100ng/ml of rhTRAIL
WT and variant 4C7. The curves in (a)–(c) represent the analysis of
10 different OVCAR-3 cells, following the TRAIL treatment. Error bars indicate the standard deviations for three single curve proﬁles using a similar number of cells.
(d) CFP/YFP ratio images of a group of OVCAR-3 cells expressing the DEVD FRET probe treated with 100ng/ml of rhTRAIL
WT and 4C7 variant
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Cell Death and Diseasewith single treatments, especially at high concentrations
(Figure 5c).
Clonogenic survival assays. To determine the effect
of these variants on long-term survival of cancer cells,
we performed clonogenic assays (Figure 6). Both DR4- and
DR5-selective variants signiﬁcantly reduced clonogenic
growth of OVCAR-3 cells when compared with rhTRAIL
WT
(Figure 6a and b). The combination of the receptor-speciﬁc
variants results in an increased ability to kill OVCAR-3 cells.
TRAIL-DISC immunoprecipitation. Analysis of the
components of the death receptor (DR) DISC formed upon
treatment with ﬂag-tag rhTRAIL
WT and ﬂag-tag rhTRAIL 4C9
indicate the ligation of DR4 and DR5 by ﬂag-tag rhTRAIL
WT.
Only DR4 but not DR5 could be pulled down in the
cells treated with ﬂag-tag rhTRAIL 4C9 (Figure 6c), further
showing the DR selectivity of these variants. In addition, the
activation of procaspase-8 within the 4C9-mediated DISC
was more pronounced than in the rhTRAIL
WT-induced DISC,
indicating a more efﬁcient activation of pro-caspase-8 by the
DR4-selective variant.
Discussion
TRAIL binds to ﬁve different receptors, of which only two are
capable of inducing apoptosis, DR4 and DR5. It is generally
accepted that decoy receptors can inhibit TRAIL-induced
apoptosis because they can bind TRAIL, but lack a functional
death domain to form the DISC.
2,9,11 However, the clarity of
this decoy concept has been blurred with the observation that
presence of decoy receptors not necessarily translates in
protection against apoptosis.
21,28 In a recent study, DcR2 has
been reported to heteromerize with DR5 to form inactive
complexes.
14–15 Heteromerization of death receptors DR4
and DR5 may also lead to inactive complexes.
7,15 In a large
number of cancer cell lines, differential contributions of the
DRs have been reported,
29 but it is not yet clear whether they
differ in their function in the apoptotic signalling. In light of
these studies, the introduction of receptor selectivity can
contribute to the elucidation of the function of each death
receptor.Suchvariantsareexpectedtohaveincreasedinvivo
activity and are candidates for new anticancer therapies.
Computational design based on the crystal structure of the
TRAIL–DR5 complex allowed the successful introduction of
DR5 selectivity by two-point mutations.
19 The highly selective
variant D269H/E195R was shown to be very efﬁcient to
induce apoptosis in an ovarian carcinoma xenograft mouse
model.
30 For DR4, a highly reﬁned homology model was
made, using data from mutational analysis.
18,19,23 A set of
21 single mutation TRAIL variants predicted to show DR4-
selective behaviour were designed, and experimentally
characterized. Two of the positions within this set were also
reported from a phage display selection study.
16 All the
21 mutants were characterized for their ability to bind
receptors and to induce apoptosis. Several mutations showed
lower afﬁnity for DR5 and higher afﬁnity for DR4. In most
cases, these effects could be well explained upon visual
inspection of the mutant models.
A representative example is given by the mutation S159R
that has a large beneﬁcial effect on the DR4/DR5 binding ratio
(Supplementary Table 1). In the WT–TRAIL–DR5 complex,
Arg-115 of DR5 forms a salt-bridge with Glu-155 and a
hydrogen bond with His-161 of TRAIL (Figure 7b). The
hydroxyl group of Ser-159 donates a hydrogen bond to
the carboxyl side chain group of Glu-155. Upon mutation of
Figure 5 DR4- and DR5-speciﬁcvariants cooperateto induce high apoptosisin
different cell lines. (a) OVCAR-3 ovarian carcinoma cell line, (b) Colo205 colon
carcinoma and (c) CL-34 colon carcinoma were treated with rhTRAIL
WT or DR4-
and DR5-speciﬁc variants (0.9–250ng/ml) alone and in combination for 24h and
assayed for cell viability. The percentage of viable cells was calculated relative to
control wells containing no ligand. The results are mean values±S.E.M. (n¼3)
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Cell Death and DiseaseSer-159 to Arg, the conformation of the side chain of Arg-115
ofDR5isslightlychangedand thehydrogenbond interactions
with His-161 are destroyed (Figure 7a).
The hydrogen bond interaction of Arg-115 with His-161 is
lost and the salt-bridge with Glu-155 is somewhat weakened.
This results in an overall loss of interaction energy for the
S159R mutation (DDGinteraction: þ1kcal/mol). On the other
hand, in the TRAIL–DR4 complex the equivalent residue
of Arg-115 is Pro-115 and, as a consequence, no direct
interactions are observed between Glu-155, Ser-159 and
His-161 of TRAIL and DR4 receptor residues (Figure 7d).
Mutation S159R allows Arg-159 to create a hydrogen
bond with the backbone oxygen atom of Cys-113 of DR4
(Figure 7c). As no interactions are destroyed with respect
to the WT situation and one new interaction is established,
there is a net gain in interaction energy (DDGinteraction:
 1.4kcal/mol). The loss in interaction energy between TRAIL
and DR5 on the one hand, and a gain in interaction energy
between TRAIL and DR4 upon Ser to Arg mutation on the
other hand, explain the observed increase in DR4 binding
speciﬁcity.
As TRAIL was reported to have a lower afﬁnity for DR4 than
to DR5,
31 a single mutation seems not sufﬁcient to produce
a variant with high afﬁnity and selectivity for DR4. Single
mutations were therefore combined based on observed
biochemical and biological properties. Two criteria were used
for the selection: (1) at least fourfold increase in DR4/DR5
binding ratio based on pre-steady state SPR measurements
and (2) at least threefold increased biological activity on DR4-
sensitive cancer cells. Nine combinations of the selected
mutations were made and most new variants showed afﬁnity
improvement to DR4 and largely reduced afﬁnity to DR5.
From these, two variants were chosen for further characteri-
zation based on their biochemical and apoptosis-inducing
characteristics: 4C7 (carrying mutations G131R/N199R/
K201H/R149I/S159R/S215D) and 4C9 (carrying G131R/
R149I/S159R/S215D). Characterization of the afﬁnities of
these two proteins for DR4 and DR5 showed that they have
not only a decreased afﬁnity for DR5, but also an increased
afﬁnity for DR4 (Table 1). The selective behaviour of these
variants was also shown by immunoprecipitation experiments
using Colo205 cells, where only DR4 but not DR5 could be
detected upon treatment with a ﬂag-tagged version of 4C9
(Figure 6c).
Variants 4C7 and 4C9 showed a remarkable capacity
to induce apoptosis in several cancer cells in vitro, including
a panel of human colon adenocarcinoma (Colo205,
SW948, DLD-1, HCT-15 and CL-34), Burkitt’s lymphoma
Figure 6 Clonogenic survival and TRAIL-DISC immunoprecipitation. (a and b) Effect of variants of rhTRAIL on the clonogenic survival of ovarian carcinoma OVCAR-3
cells. One hundred (a) and two hundred (b) OVCAR-3 cells were seeded as single cells, and treated with 5ng/ml of rhTRAIL
WT or variants for 24h. After recovering for
14 days, colony formation was determined. (c) Colo205 cells were treated with 250ng/ml ﬂag-tag rhTRAIL
WT (WT) or ﬂag-tag rhTRAIL 4C9 (4C9) or left untreated (control)
for 15min. The cells were harvested and the ligated DISC complexes immunoprecipitated using an anti-FLAG antibody. The presence of DR4, DR5 and caspase-8 in the
DISC was detected using western blotting. *A nonspeciﬁc band detected by the DR5 and caspase-8 antibody
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Cell Death and Disease(BJAB), pancreatic carcinoma (PANC-1), the human ovarian
carcinoma OVCAR-3 and human breast adenocarcinoma
MCF-7cancercellline.Thecoloncarcinomacelllinesshowed
values ranging from three- to 10-fold increased cell death
induction by 4C7 and 4C9 when compared with rhTRAIL
WT
(Figure 3). The lack of activity on DR5-mediated A2780
and Jurkat cells and the comparison of activity between BJAB
and BJAB DR5-deﬁcient cell line with rhTRAIL
WT clearly
conﬁrmed the DR4 selectivity of the variants 4C7 and 4C9
(Figure 2). The increased activity of the variants was also
evidentinTRAIL-resistantMCF-7andPANC-1cells(Figure3).
The higher afﬁnity and selectivity of our variants for DR4
(Table1andFigure1)seemstocorrelatetotheirhighercellular
activity in cell lines sensitive via the DR4 receptor.
To further analyse the activity of the variant 4C7, we
determined caspase activation in OVCAR-3 cells using FRET
and ﬂuorescent probes (Figure 4). A much faster and stronger
onset of caspase activation could be observed for 4C7 in
comparisontorhTRAIL
WT caspase-8/10activationasseenby
the IETDase probe cleavage that started already at very
early time points with a nearly eightfold faster activation when
compared with rhTRAIL
WT (Figure 4a and b). Downstream
effector caspase activation based on DEVDase activity using
a probe containing CFP and YFP indicated a signiﬁcant
cleavage rate starting at 75min over a 30–40min period for
4C7(Figure4candd).DEVDasecleavageforrhTRAIL
WTwas
substantially slower in the time points taken. These results
allow us to conclude that variant 4C7 induces a much faster
and robust initiator and effector caspase activation than
rhTRAIL
WT in the OVCAR-3 cell line, and underlines the
efﬁcacy of the DR4-speciﬁc variant.
The high efﬁcacy of our new DR4-selective variants in
addition to the earlier published DR5 variant D269H/E195R
19
inspired us to test whether their combination would lead to
even higher apoptotic activity. Combination treatment using
the DR4-selective variants with the DR5-selective variant
enhanced apoptosis-inducing activity when compared with
the responses obtained for the single treatments (Figure 5).
Analysis of response curves using different concentrations of
DR-speciﬁc variants in combination indicates a signiﬁcant
additive effect on cell death induction on the ovarian
carcinoma OVCAR-3 cell line. A similar effect was observed
in colon carcinoma cell lines Colo205 and CL-34 at high
concentrations of the two TRAIL variants. Even though part of
the effect can be explained by the higher afﬁnities and higher
association rate constants of these variants for their cognate
receptor, these results also point to the inability of these
variants to form inactive heteromeric receptor complexes
between their target DR and the other receptors, as
was shown for rhTRAIL
WT. Furthermore, our DR4- and
DR5-selective variants strongly inhibited clonogenicity of
OVCAR-3 ovarian carcinoma cells (Figure 6a and b), showing
the enhanced efﬁcacy of these variants compared with
rhTRAIL
WT in reducing long-term survival of cancer cells.
Figure7 Structuralimpressionsoftheareaaround159forS159RandrhTRAIL
WTasdeterminedbyFoldX:(aandb)TRAIL-DR5and(candd)TRAIL-DR4.Thesubunits
of TRAIL are depicted in lime and receptors in green. The template selected was 1D4V, the structure at 2.2A ˚ resolution and of monomeric human TRAIL in complex with the
ectodomain of DR5 receptor. The homotrimer was generated using the protein quaternary structure server from the EBI (http://pqs.ebi.ac.uk), having the symmetry
coordinates in the PDB ﬁle
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leadtotheformationofhigh-afﬁnity homotrimericTRAIL–DR4
complexes. These TRAIL variants alone or in combination
with our DR5 agonist may prove to be a promising treatment
for a range of different cancers.
Materials and Methods
Modelling and computational design of variants using
FoldX. Currently, only the crystal structure of TRAIL alone or in complex with
DR5 is known. A homology model of DR4 was built based on the coordinates of
TRAIL and DR5, from the template TRAIL in complex with the ectodomain of DR5,
pdb: ID 1D4V,
32 using the high sequence identity between DR5 and DR4 (450%),
with no insertions or deletions between both death receptors. Binding effects of
mutationssituatedintheTRAIL–receptorinterface
18,23allowedtheconstructionofa
reﬁned homology model for the TRAIL–DR4 complex using the protein design
capabilities of FoldX.
33,34These coordinateswere usedto constructthehomotrimer
TRAIL using the protein quaternary structure server from EBI (http://pqs.ebi.ac.uk).
Single mutants of TRAIL were predicted by FoldX. Interaction energies were
calculated as the sum of the energies of the individual receptor and ligand subunits
and subtracting them from the global energy of the complex. A detailed description
of the protein design algorithm FoldX (version 3.0) is available elsewhere in
http://foldx.crg.es.
Construction, expression and puriﬁcation of rhTRAIL
variants. Mutants were constructed by PCR reaction using the megaprimer
mutagenesis method. The polymerase used was Phusion polymerase supplied by
Finnzymes (Espoo, Finland). Introduction of mutations was conﬁrmed by DNA
sequencing. RhTRAIL
WT and variants were cloned into pET15b (Novagen, Madison,
WI,USA)usingtheBamHIandNcoIsitesand transformedintoEscherichiacoliBL21
(DE3). Homotrimeric TRAIL proteins were expressed and puriﬁed as described
before.
19,23 Flag-tag rhTRAIL
WT and ﬂag-tag rhTRAIL 4C9 were constructed by
introducing the sequence encoding a ﬂag-tag N-terminally of the rhTRAIL (aa
114–281) sequence in pET15b. Analytical gel ﬁltration, dynamic light scattering and
non-reducing gel electrophoresis conﬁrmed that rhTRAIL
WT and variants were stable
trimeric molecules and did not form higher-order molecular weight aggregates.
Receptor binding by surface plasmon resonance and
competitive ELISA. Binding experiments were performed using a surface
plasmon resonance-based Biacore 3000 (GE Healthcare, Eindhoven, The
Netherlands). Research grade CM4 sensor chips, N-hydroxysuccimide, N-ethyl-
N0-(3-diethylaminopropyl) carbodiimide, ethanolamine hydrochloride and standard
buffers, for example, HBS-N, were purchased from the manufacturer (GE
Healthcare). Immobilization of Staphylococcal protein A (Sigma, Zwijndrecht, The
Netherlands)onthesensorsurfaceofaCM4sensorchipwasperformedfollowinga
standard amine coupling procedure. Protein A was coated at a level of B1000
response units. DR4-Ig and DR5-Ig receptors (R&D Systems, Minneapolis, MN,
USA) were captured at high ﬂow rate to low densities (5–20RU) resulting in binding
of a trimeric TRAIL molecule to only one receptor molecule and allowing global
ﬁtting of the data to a 1:1 Langmuir model.
35 A 100ml aliquot of rhTRAIL
WT and
variantswasinjectedatconcentrationsrangingfrom1to 250nMat 50ml/minandat
371C using HBS-N supplemented with 0.005% surfactant P20 as running and
sample buffer. Binding of ligands to the receptors was monitored in real time.
Between cycles, the protein A/sensor surface was regenerated using 10mM
glycine, pH 1.7 and a contact time of 25s.
For competitive ELISA, Nunc maxisorb plates were coated for 2h with DR4-Ig
(100ng per well) in 0.1M sodium carbonate/bicarbonate buffer (pH 8.6) and the
remaining binding places subsequently blocked with 2% BSA for 1h. After washing
six times with Tris-buffered saline/0.5% Tween-20 (TBST) (pH 7.5), serial dilutions
of soluble DR4-, DR5-, DcR1- or DcR2-Ig (0–5000ng/ml) and rhTRAIL
WT or
mutants (100ng/ml) in PBS (pH 7.4) previously incubated for 1.5h at room
temperature were added to the wells and incubated for 1h. After washing, a 1:200
dilution of anti-TRAIL antibody (R&D Systems) was added and incubated for 1h at
room temperature, and, after washing with TBST, subsequently incubated with a
1:25000dilutionofahorseradishperoxidase-conjugatedswineanti-goatantibody.
Finally, a 100ml of one-step Turbo TMB solution (Pierce, Rockford, IL, USA) was
added. The reaction was quenched with 100ml of 1M sulphuric acid and the
absorbance measured at 450nm on a microplate reader (Thermo Labsystems,
Breda,TheNetherlands).BindingofrhTRAILorvariantstoimmobilizedDR4-Igwith
0ng per well of the soluble receptors was taken as 100%, and binding at other
concentrations of soluble receptors was calculated relative to this value.
Reagents and cell line treatment. Cell culture reagents were purchased
from Gibco (Invitrogen, Breda, The Netherlands). Cycloheximide was from Sigma-
Aldrich(Zwijndrecht,TheNetherlands).Colonadenocarcinomacelllines Colo205,DLD-
1andHCT-15,Burkitt’slymphoma(BJAB),JurkatT-cellleukaemiaandPANC-1human
pancreatic carcinoma cell lines were maintained in RPMI 1640 medium, supplemented
with 10% FBS, 50U/ml penicillin, 5mg/ml streptomycin, 2mM L-glutamine and 1mM
sodium pyruvate in a humidiﬁed incubator at 371C and 5% CO2 environment. A2780
ovarian carcinoma, MFC-7 human breast adenocarcinoma and OVCAR-3 ovarian
carcinoma were cultured in DMEM, with 10% FBS, 50U/ml penicillin, 5mg/ml
streptomycin and glutamine. Colon carcinoma SW948 cells were cultured in Leibovitz
L15-RPMI 1640 (1:1) enriched with 10% FBS, 0.05M pyruvate, 0.1M glutamine and
0.025% b-mercaptoethanol at 371C in a humidiﬁed atmosphere with 5% CO2. All cells
were seeded at 50% conﬂuence 24h before treatment.
TRAIL receptor expression in cell lines. Cells were removed from
culture dishes, harvested by centrifugation and washed twice with 1% BSA in PBS.
Cells were incubated with 1:100 dilution of primary antibodies DR4 and DR5:
neutralizingmousemonoclonal antibodies(Alexis,SanDiego,CA,USA);DcR1and
DcR2: neutralizinggoat polyclonal antibodies(R&D Systems)in 1% BSA in PBS for
40min on ice. After two washes with 1% BSA in PBS, cells were resuspended in
1:50 dilution of FITC-labelled secondary antibody and incubated for 40min on ice.
Excess secondary antibody was removed by washing ﬁrst in 1% BSA in PBS and
then PBS. Cells were ﬁxed in 1% formaldehyde/PBS before analysis by ﬂow
cytometry (FacsCalibur, Beckton Dickinson, San Jose, CA, USA).
Cell viability and apoptosis assays. To determine sensitivity to rhTRAIL
andvariants,cellswereplatedin96-wellplates,allowedto adherefor 24handthen
treated with rhTRAIL in various concentrations, ranging from 1 to 250ng/ml. After
24h incubation, the cells were subjected to an MTS viability assay (Promega,
Leiden, The Netherlands) following the manufacturer’s protocol. Cell viability was
determined after 1–2h of incubation by measuring the absorption at 490nm on a
microplate reader (Thermo Labsystems). Apoptosis induction was measured by
AnnexinVstainingandquantiﬁedbyﬂowcytometricanalysisasdescribedbefore.
23
Live cell microscopy: caspase activation in living cells using
FRET. Time lapse images were collected using a Leica SP2 AOBS CLSM
microscope equipped with an environmental chamber at 371C and 5% CO2 and
 10 or  20 objective magniﬁcation. Images were collected every minute.
OVCAR-3 ovarian carcinoma cell line expressing pSCAT8 producing CFP-IETD-
Venus
25 and pDEVD containing CFP-DEVD-YFP
36 were derived by transfection
with Fugene 6 (Roche, Almere, The Netherlands) according to the manufacturer’s
protocol. Plasmids pSCAT8 and pDEVD were a kind gift from Dr. Markus Rehm.
Ratio images were obtained using the Image J software and available custom
pluginsbycalculatingtheratiofromtheobtainedCFPandYFPimagescorrectedfor
background. Signals were normalized by subtracting the minimum value across all
time points from each single time-course experiment.
Clonogenic survival assay. The clonogenic ability of ovarian carcinoma
cells (OVCAR-3) was determined by plating the cells at the appropriate dilutions in
DMEMmedium,treatedfor24hwithrhTRAIL
WTandvariantsandthecolonieswere
counted after 2 weeks. Brieﬂy, 100 or 200 cells were plated out in 94mm Petri
dishes (Greiner) in 10ml DMEM medium containing 10% fetal bovine serum
(Invitrogen), penicillin(10U/ml) and streptomycin(10mg/ml), andincubated for 16h
at 371C and 5% CO2. The cells were treated with 5ng/ml of rhTRAIL
WT or variants
for 24h. After treatment, the medium was replaced and cells incubated for 2 weeks
at 371C and 5% CO2. The colonies were ﬁxed and stained using 0.1% Brilliant blue
(Sigma), 50% methanol and 10% acetic acid, and destained with wash buffer (10%
methanol and 7% acetic acid). Colonies containing more than 50 cells were scored.
TRAIL-DISC immunoprecipitation. The anti-FLAG (M2 antibody, Sigma)
was covalently conjugated to epoxy-coated Dynabeads (Invitrogen) following the
manufacturer’s instructions (5mg antibody per 1mg bead). Colo205 cells
(approximately 50mg per sample) were treated with 250ng/ml ﬂag-tag
rhTRAIL
WT or ﬂag-tag rhTRAIL 4C9 for 15min. Cells were harvested by scraping
in the medium and centrifugation. After washing with PBS, the cell pellet was
weighted and the cells lysed with nine volumes of Extraction buffer A (Dynabeads
Tumour killing by death receptor homotrimerizing TRAIL variants
CR Reis et al
9
Cell Death and DiseaseCo-immunoprecipitation kit, Invitrogen) supplemented with 50mM NaCl and
incubated on ice for 15min. The lysates were cleared by centrifugation and mixed
with 1.5mg of antibody-coupled Dynabeads. The lysates were rotated with the
beadsfor3hat41C,afterwhichthesupernatantwasseparatedfromthebeads,the
beads washed and the DISC complex eluted by following the manufacturer’s
instructions. The immunoprecipitate was denatured in Laemmli buffer before
loading on gels and analysis of the DISC components.
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